Immune Design Corp (NASDAQ:IMDZ) has received a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $7.25.
Several analysts have weighed in on IMDZ shares. Zacks Investment Research upgraded shares of Immune Design from a “sell” rating to a “hold” rating in a research note on Wednesday, October 3rd. HC Wainwright began coverage on shares of Immune Design in a research report on Wednesday, August 29th. They set a “buy” rating and a $11.00 price target for the company. Royal Bank of Canada restated an “outperform” rating and set a $11.00 price target on shares of Immune Design in a research report on Friday, October 12th. Finally, Leerink Swann lowered shares of Immune Design from an “outperform” rating to a “market perform” rating in a research report on Friday, October 12th.
IMDZ stock opened at $1.66 on Friday. Immune Design has a 1-year low of $1.47 and a 1-year high of $6.55. The firm has a market cap of $166.17 million, a price-to-earnings ratio of -0.95 and a beta of 1.77.
Several institutional investors have recently added to or reduced their stakes in IMDZ. Tiverton Asset Management LLC bought a new position in shares of Immune Design during the second quarter worth about $176,000. Essex Investment Management Co. LLC bought a new position in shares of Immune Design during the second quarter worth about $192,000. Bank of America Corp DE grew its position in shares of Immune Design by 231.9% during the second quarter. Bank of America Corp DE now owns 46,754 shares of the biotechnology company’s stock worth $212,000 after acquiring an additional 32,669 shares during the last quarter. DRW Securities LLC grew its position in shares of Immune Design by 59.2% during the second quarter. DRW Securities LLC now owns 58,900 shares of the biotechnology company’s stock worth $268,000 after acquiring an additional 21,900 shares during the last quarter. Finally, Alps Advisors Inc. bought a new position in Immune Design in the 2nd quarter valued at about $318,000. Institutional investors and hedge funds own 49.41% of the company’s stock.
About Immune Design
Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.
Read More: Retained Earnings
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.